FOXP3 and neoplasm: Patients with CD4+ tumours were found to have OS and disease-free survival (DFS) higher than patients with CD4- tumours, and a high CD8+/FoxP3+ lymphocyte ratio correlated with better clinical outcomes, but no significant correlation was found between CD8+ TILs and survival or other clinical-pathological features [8].